Agilent Technologies (NYSE:A) Given New $165.00 Price Target at Barclays

Agilent Technologies (NYSE:A) had its target price upped by Barclays from $145.00 to $165.00 in a research note issued to investors on Tuesday,Benzinga reports. Barclays currently has an equal weight rating on the medical research company’s stock.

A number of other research firms also recently commented on A. Weiss Ratings reissued a “hold (c)” rating on shares of Agilent Technologies in a research note on Wednesday, October 8th. Rothschild & Co Redburn started coverage on shares of Agilent Technologies in a report on Wednesday, October 8th. They issued a “buy” rating and a $165.00 price target for the company. Wells Fargo & Company lifted their price objective on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, September 15th. Bank of America increased their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, Rothschild Redb upgraded shares of Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $161.08.

Agilent Technologies Trading Up 2.4%

Shares of NYSE:A opened at $157.25 on Tuesday. The company has a 50 day moving average of $140.80 and a 200-day moving average of $126.03. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The firm has a market cap of $44.58 billion, a P/E ratio of 36.91, a P/E/G ratio of 4.67 and a beta of 1.29. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $160.27.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.01. The business had revenue of $1.86 billion for the quarter, compared to analyst estimates of $1.83 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the business earned $1.46 earnings per share. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS. As a group, analysts anticipate that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Stockholders of record on Tuesday, January 6th will be given a $0.255 dividend. This represents a $1.02 annualized dividend and a dividend yield of 0.6%. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.25. The ex-dividend date of this dividend is Tuesday, January 6th. Agilent Technologies’s payout ratio is 23.94%.

Insider Activity at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 911 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $143.24, for a total value of $130,491.64. Following the completion of the sale, the chief executive officer owned 32,058 shares in the company, valued at approximately $4,591,987.92. This represents a 2.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.26% of the company’s stock.

Institutional Trading of Agilent Technologies

Large investors have recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in shares of Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after buying an additional 270 shares during the period. Cetera Investment Advisers raised its position in Agilent Technologies by 8.1% during the first quarter. Cetera Investment Advisers now owns 36,267 shares of the medical research company’s stock valued at $4,243,000 after buying an additional 2,723 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Agilent Technologies by 4.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 236,725 shares of the medical research company’s stock worth $27,692,000 after acquiring an additional 11,079 shares in the last quarter. LPL Financial LLC boosted its position in Agilent Technologies by 3.8% during the 1st quarter. LPL Financial LLC now owns 121,147 shares of the medical research company’s stock worth $14,172,000 after acquiring an additional 4,468 shares during the period. Finally, Mackenzie Financial Corp grew its stake in Agilent Technologies by 141.5% during the 1st quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock valued at $109,481,000 after acquiring an additional 548,344 shares in the last quarter. 87.41% of the stock is owned by institutional investors and hedge funds.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.